ARROWHEAD PHARMACEUTICALS INC
Arrowhead Pharmaceuticals (ARWR) is a clinical-stage biopharmaceutical company focused on developing RNA interference (RNAi) therapeutics. Using a proprietary delivery platform designed to silence specific genes, Arrowhead advances candidates aimed primarily at liver-related diseases and other conditions where gene knockdown may be therapeutic. The business model is R&D‑driven: value tends to be tied to clinical milestones, regulatory progress and partnerships rather than stable product revenue. Investors should note the binary nature of clinical outcomes, the time and capital typically required to bring experimental therapies to market, and the potential for significant share-price volatility around trial results and deal announcements. The company may partner or licence programmes to larger pharmaceutical groups to share development risk and access commercial expertise. This summary is for educational purposes only and not investment advice; individual suitability depends on personal circumstances and risk tolerance.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Arrowhead Pharmaceuticals stock as it has good potential for growth.
Financial Health
Arrowhead Pharmaceuticals is generating strong revenue and cash flow, indicating healthy financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring ARWR
Pioneers Of Safer Gene Therapies
Discover a carefully selected group of innovative companies developing alternatives to traditional viral vector gene therapies. These stocks represent biotechs working on potentially safer genetic medicine technologies like siRNA and antisense oligonucleotides, handpicked by professional analysts for their pioneering approaches.
Published: July 21, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage pipeline
Progress in human trials can materially change valuation, so clinical read-outs are worth watching — though outcomes are binary and can be unpredictable.
RNAi platform focus
A platform approach can create multiple opportunities if delivery and safety perform well, but technical and regulatory hurdles remain.
Partnerships and deals
Collaborations with larger pharma can de‑risk development and provide milestones, yet deal terms and reliance on partners also shape future returns.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
